Results 31 to 40 of about 245,199 (308)

Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis

open access: yesPediatric Rheumatology Online Journal, 2017
Background Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients.
Sonja Falvey   +3 more
doaj   +1 more source

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. [PDF]

open access: yes, 2016
IntroductionTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical ...
DeMasi, Ryan   +6 more
core   +3 more sources

Adverse Aftereffects of Methotrexate as Chemotherapy on Cognitive Deficits in Rat Models [PDF]

open access: yes, 2020
Patients with acute lymphoblastic leukemia have a high five-year survival rate thanks to methotrexate (MTX). However, cognitive side effects are reported, characterized as chemo brain.
Kang, Jubin
core   +1 more source

The role of nitric oxide in small intestine differs between a single and a consecutive administration of methotrexate to rats

open access: yesJournal of Pharmacological Sciences, 2020
The role of nitric oxide (NO) on intestinal mucosal injury induced by single or consecutive administration of methotrexate was investigated in a rodent model. Rats received methotrexate intraperitoneally either as a single administration (50 mg/kg) or as
Saki Shiga   +5 more
doaj   +1 more source

Preferences of Pediatric Patients and Their Caregivers for Chemotherapy‐Induced Nausea and Vomiting Control Endpoints: A Mixed Methods Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Although not always achieved, complete chemotherapy‐induced nausea and vomiting (CINV) control is the conventional goal of CINV prophylaxis. In this two‐center, mixed‐methods study, we sought to understand the preferences of adolescent patients and family caregivers for CINV control endpoints.
Haley Newman   +8 more
wiley   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis. [PDF]

open access: yes, 2019
Background Long-term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long-term corticosteroid-sparing immunosuppression in CS is unknown.
Benn, Bryan S   +17 more
core  

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

open access: yes, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas   +173 more
core   +2 more sources

The newfound relationship between extrachromosomal DNAs and excised signal circles

open access: yesFEBS Letters, EarlyView.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Methotrexate-induced acute neurotoxicity in patients with osteosarcoma: a case report

open access: yesJournal of Medical Case Reports
Background Methotrexate is commonly used to treat osteosarcoma and acute lymphoblastic leukemia. Methotrexate can rarely cause neurotoxicity with a wide range of presentations including seizure, hemiparesis, dysarthria, dysphagia, and more.
Olivia L. Makos   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy